CN112955185A - 联合基因治疗 - Google Patents
联合基因治疗 Download PDFInfo
- Publication number
- CN112955185A CN112955185A CN201980042058.3A CN201980042058A CN112955185A CN 112955185 A CN112955185 A CN 112955185A CN 201980042058 A CN201980042058 A CN 201980042058A CN 112955185 A CN112955185 A CN 112955185A
- Authority
- CN
- China
- Prior art keywords
- transgene
- vector
- type
- combination therapy
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001415 gene therapy Methods 0.000 title abstract description 27
- 238000002648 combination therapy Methods 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 24
- 108700019146 Transgenes Proteins 0.000 claims description 109
- 210000004027 cell Anatomy 0.000 claims description 104
- 239000013598 vector Substances 0.000 claims description 104
- 239000013603 viral vector Substances 0.000 claims description 84
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 108091033319 polynucleotide Proteins 0.000 claims description 28
- 102000040430 polynucleotide Human genes 0.000 claims description 28
- 239000002157 polynucleotide Substances 0.000 claims description 28
- 108020004999 messenger RNA Proteins 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 102000014914 Carrier Proteins Human genes 0.000 claims description 11
- 108091008324 binding proteins Proteins 0.000 claims description 11
- 210000001808 exosome Anatomy 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 108020001507 fusion proteins Proteins 0.000 claims description 8
- 102000037865 fusion proteins Human genes 0.000 claims description 8
- 108091054442 EV proteins Proteins 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 7
- 108091028075 Circular RNA Proteins 0.000 claims description 5
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 5
- 208000016361 genetic disease Diseases 0.000 claims description 5
- 241000702421 Dependoparvovirus Species 0.000 claims description 4
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 4
- 208000012268 mitochondrial disease Diseases 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 241001430294 unidentified retrovirus Species 0.000 claims description 4
- 241000713666 Lentivirus Species 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- 230000005856 abnormality Effects 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 241000709687 Coxsackievirus Species 0.000 claims description 2
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 201000009623 Myopathy Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000012239 gene modification Methods 0.000 claims description 2
- 230000005017 genetic modification Effects 0.000 claims description 2
- 235000013617 genetically modified food Nutrition 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 230000000858 peroxisomal effect Effects 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims 1
- 208000024556 Mendelian disease Diseases 0.000 abstract description 6
- 238000001476 gene delivery Methods 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 4
- 201000002200 Congenital disorder of glycosylation Diseases 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 208000011580 syndromic disease Diseases 0.000 description 17
- 239000000203 mixture Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 238000011068 loading method Methods 0.000 description 13
- 230000028993 immune response Effects 0.000 description 11
- 108700005077 Viral Genes Proteins 0.000 description 10
- 238000009295 crossflow filtration Methods 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 10
- 210000002889 endothelial cell Anatomy 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 description 9
- 231100000241 scar Toxicity 0.000 description 9
- 206010003591 Ataxia Diseases 0.000 description 8
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 8
- -1 hnRNPA2B Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000013607 AAV vector Substances 0.000 description 7
- 208000033237 Aicardi-Goutières syndrome Diseases 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 238000004811 liquid chromatography Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000010361 transduction Methods 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 208000021075 Creatine deficiency syndrome Diseases 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 201000008609 cerebral creatine deficiency syndrome Diseases 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 210000003425 amniotic epithelial cell Anatomy 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 201000007601 neurodegeneration with brain iron accumulation Diseases 0.000 description 5
- 210000002826 placenta Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 208000015872 Gaucher disease Diseases 0.000 description 4
- 101000692464 Homo sapiens Platelet-derived growth factor receptor-like protein Proteins 0.000 description 4
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 208000030162 Maple syrup disease Diseases 0.000 description 4
- 208000008955 Mucolipidoses Diseases 0.000 description 4
- 102100026554 Platelet-derived growth factor receptor-like protein Human genes 0.000 description 4
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 230000016784 immunoglobulin production Effects 0.000 description 4
- 208000024393 maple syrup urine disease Diseases 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000004114 suspension culture Methods 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 201000011296 tyrosinemia Diseases 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- 102100026444 Arrestin domain-containing protein 1 Human genes 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 3
- 102100025222 CD63 antigen Human genes 0.000 description 3
- 108020004638 Circular DNA Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 208000032274 Encephalopathy Diseases 0.000 description 3
- 201000008892 GM1 Gangliosidosis Diseases 0.000 description 3
- 101000785762 Homo sapiens Arrestin domain-containing protein 1 Proteins 0.000 description 3
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 208000024929 Mucopolysaccharidosis type 2, attenuated form Diseases 0.000 description 3
- 206010033892 Paraplegia Diseases 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- 102100033344 Programmed cell death 6-interacting protein Human genes 0.000 description 3
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 208000032930 Spastic paraplegia Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 208000033539 attenuated form mucopolysaccharidosis type 2 Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000011026 diafiltration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 239000012510 hollow fiber Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 201000001204 progressive myoclonus epilepsy Diseases 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 2
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 2
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000015012 Autosomal recessive progressive external ophthalmoplegia Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 102100027221 CD81 antigen Human genes 0.000 description 2
- 102100037904 CD9 antigen Human genes 0.000 description 2
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 2
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 2
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000024720 Fabry Disease Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 2
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 2
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 2
- 101001083553 Homo sapiens Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 description 2
- 101000728117 Homo sapiens Plasma membrane calcium-transporting ATPase 4 Proteins 0.000 description 2
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 2
- 101000794187 Homo sapiens Tetraspanin-18 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 2
- 208000006136 Leigh Disease Diseases 0.000 description 2
- 208000017507 Leigh syndrome Diseases 0.000 description 2
- 108010051910 Long-chain-3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 2
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 2
- 208000037547 Mitochondrial myopathy and sideroblastic anemia Diseases 0.000 description 2
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 2
- 208000010577 Niemann-Pick disease type C Diseases 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 201000002786 Perrault syndrome Diseases 0.000 description 2
- 102100029743 Plasma membrane calcium-transporting ATPase 4 Human genes 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102100040120 Prominin-1 Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 208000025816 Sanfilippo syndrome type A Diseases 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- 102000019361 Syndecan Human genes 0.000 description 2
- 108050006774 Syndecan Proteins 0.000 description 2
- 102100035721 Syndecan-1 Human genes 0.000 description 2
- 102100026087 Syndecan-2 Human genes 0.000 description 2
- 102100030175 Tetraspanin-18 Human genes 0.000 description 2
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 description 2
- 238000004115 adherent culture Methods 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- SHZGCJCMOBCMKK-PHYPRBDBSA-N alpha-D-fucose Chemical compound C[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-PHYPRBDBSA-N 0.000 description 2
- 238000002669 amniocentesis Methods 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 208000012892 autosomal dominant progressive external ophthalmoplegia Diseases 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003013 erythroid precursor cell Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000012537 formulation buffer Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 210000005073 lymphatic endothelial cell Anatomy 0.000 description 2
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 2
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 208000036710 mucopolysaccharidosis type 3A Diseases 0.000 description 2
- 208000012226 mucopolysaccharidosis type IIIA Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000004479 myeloid suppressor cell Anatomy 0.000 description 2
- 201000010256 myopathy, lactic acidosis, and sideroblastic anemia Diseases 0.000 description 2
- 108700043045 nanoluc Proteins 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000009984 peri-natal effect Effects 0.000 description 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 208000037118 sensory ataxia Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- IYLGZMTXKJYONK-ACLXAEORSA-N (12s,15r)-15-hydroxy-11,16-dioxo-15,20-dihydrosenecionan-12-yl acetate Chemical compound O1C(=O)[C@](CC)(O)C[C@@H](C)[C@](C)(OC(C)=O)C(=O)OCC2=CCN3[C@H]2[C@H]1CC3 IYLGZMTXKJYONK-ACLXAEORSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- BSDCIRGNJKZPFV-GWOFURMSSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(2,5,6-trichlorobenzimidazol-1-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=CC(Cl)=C(Cl)C=C2N=C1Cl BSDCIRGNJKZPFV-GWOFURMSSA-N 0.000 description 1
- KZKAYEGOIJEWQB-UHFFFAOYSA-N 1,3-dibromopropane;n,n,n',n'-tetramethylhexane-1,6-diamine Chemical compound BrCCCBr.CN(C)CCCCCCN(C)C KZKAYEGOIJEWQB-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- AGJBKFAPBKOEGA-UHFFFAOYSA-M 2-methoxyethylmercury(1+);acetate Chemical compound COCC[Hg]OC(C)=O AGJBKFAPBKOEGA-UHFFFAOYSA-M 0.000 description 1
- 102000052553 3-Hydroxyacyl CoA Dehydrogenase Human genes 0.000 description 1
- 108700020831 3-Hydroxyacyl-CoA Dehydrogenase Proteins 0.000 description 1
- 208000026222 3-hydroxyisobutyryl-CoA hydrolase deficiency Diseases 0.000 description 1
- LDTAOIUHUHHCMU-UHFFFAOYSA-N 3-methylpent-1-ene Chemical compound CCC(C)C=C LDTAOIUHUHHCMU-UHFFFAOYSA-N 0.000 description 1
- 102100033391 ATP-dependent RNA helicase DDX3X Human genes 0.000 description 1
- 208000019932 Aciduria Diseases 0.000 description 1
- 208000005223 Alkalosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 101100233760 Arabidopsis thaliana JAG gene Proteins 0.000 description 1
- 208000034318 Argininemia Diseases 0.000 description 1
- 206010058298 Argininosuccinate synthetase deficiency Diseases 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 108090000328 Arrestin Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100028820 Aspartate-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- 206010068220 Aspartylglucosaminuria Diseases 0.000 description 1
- 208000004724 Ataxia neuropathy spectrum Diseases 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 description 1
- 208000026553 Autosomal dominant optic atrophy, classic form Diseases 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- 102100032412 Basigin Human genes 0.000 description 1
- 108700017401 Beta-Hydroxyisobutyryl CoA Deacylase Deficiency Proteins 0.000 description 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- 102100032487 Beta-mannosidase Human genes 0.000 description 1
- 208000005977 Bjornstad syndrome Diseases 0.000 description 1
- 101150033066 CD101 gene Proteins 0.000 description 1
- 102100035893 CD151 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 102100024853 Carnitine O-palmitoyltransferase 2, mitochondrial Human genes 0.000 description 1
- 206010058892 Carnitine deficiency Diseases 0.000 description 1
- 201000002929 Carnitine palmitoyltransferase II deficiency Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 201000008992 Charcot-Marie-Tooth disease type 1B Diseases 0.000 description 1
- 101100499417 Chlamydia pneumoniae dnaA1 gene Proteins 0.000 description 1
- 208000035374 Chronic visceral acid sphingomyelinase deficiency Diseases 0.000 description 1
- 201000011297 Citrullinemia Diseases 0.000 description 1
- 208000010354 Coenzyme Q10 deficiency Diseases 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 101150073133 Cpt1a gene Proteins 0.000 description 1
- 206010011777 Cystinosis Diseases 0.000 description 1
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 description 1
- 102100029581 DDB1- and CUL4-associated factor 17 Human genes 0.000 description 1
- 208000011518 Danon disease Diseases 0.000 description 1
- 102100033672 Deleted in azoospermia-like Human genes 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101000836492 Dictyostelium discoideum ALG-2 interacting protein X Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101100010303 Drosophila melanogaster PolG1 gene Proteins 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 1
- 102100033238 Elongation factor Tu, mitochondrial Human genes 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000007686 GLUT1 deficiency syndrome Diseases 0.000 description 1
- 201000008393 GM1 gangliosidosis type 1 Diseases 0.000 description 1
- 201000008394 GM1 gangliosidosis type 2 Diseases 0.000 description 1
- 201000007767 GM1 gangliosidosis type 3 Diseases 0.000 description 1
- 208000001905 GM2 Gangliosidoses Diseases 0.000 description 1
- 201000008905 GM2 gangliosidosis Diseases 0.000 description 1
- 208000013381 GRACILE syndrome Diseases 0.000 description 1
- 102100040510 Galectin-3-binding protein Human genes 0.000 description 1
- 208000020322 Gaucher disease type I Diseases 0.000 description 1
- 208000020916 Gaucher disease type II Diseases 0.000 description 1
- 208000028735 Gaucher disease type III Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108700006771 Glut1 Deficiency Syndrome Proteins 0.000 description 1
- 102100030651 Glutamate receptor 2 Human genes 0.000 description 1
- 102100030669 Glutamate receptor 3 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108700006770 Glutaric Acidemia I Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000001500 Glycogen Storage Disease Type IIb Diseases 0.000 description 1
- 208000035148 Glycogen storage disease due to LAMP-2 deficiency Diseases 0.000 description 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
- 239000000899 Gutta-Percha Substances 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 108010024164 HLA-G Antigens Proteins 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 102100033985 Heterogeneous nuclear ribonucleoprotein D0 Human genes 0.000 description 1
- 102100028909 Heterogeneous nuclear ribonucleoprotein K Human genes 0.000 description 1
- 102100028895 Heterogeneous nuclear ribonucleoprotein M Human genes 0.000 description 1
- 102100028896 Heterogeneous nuclear ribonucleoprotein Q Human genes 0.000 description 1
- 102100024002 Heterogeneous nuclear ribonucleoprotein U Human genes 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000870662 Homo sapiens ATP-dependent RNA helicase DDX3X Proteins 0.000 description 1
- 101000696909 Homo sapiens Aspartate-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101001000001 Homo sapiens Basement membrane-specific heparan sulfate proteoglycan core protein Proteins 0.000 description 1
- 101000798441 Homo sapiens Basigin Proteins 0.000 description 1
- 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 description 1
- 101000946874 Homo sapiens CD151 antigen Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 1
- 101000909313 Homo sapiens Carnitine O-palmitoyltransferase 2, mitochondrial Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101000917433 Homo sapiens DDB1- and CUL4-associated factor 17 Proteins 0.000 description 1
- 101000871280 Homo sapiens Deleted in azoospermia-like Proteins 0.000 description 1
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 description 1
- 101000967904 Homo sapiens Galectin-3-binding protein Proteins 0.000 description 1
- 101001010449 Homo sapiens Glutamate receptor 2 Proteins 0.000 description 1
- 101001010434 Homo sapiens Glutamate receptor 3 Proteins 0.000 description 1
- 101001017535 Homo sapiens Heterogeneous nuclear ribonucleoprotein D0 Proteins 0.000 description 1
- 101000838964 Homo sapiens Heterogeneous nuclear ribonucleoprotein K Proteins 0.000 description 1
- 101000839073 Homo sapiens Heterogeneous nuclear ribonucleoprotein M Proteins 0.000 description 1
- 101000839069 Homo sapiens Heterogeneous nuclear ribonucleoprotein Q Proteins 0.000 description 1
- 101001047854 Homo sapiens Heterogeneous nuclear ribonucleoprotein U Proteins 0.000 description 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101001015006 Homo sapiens Integrin beta-4 Proteins 0.000 description 1
- 101000599858 Homo sapiens Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 101000875582 Homo sapiens Isoleucine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101001034314 Homo sapiens Lactadherin Proteins 0.000 description 1
- 101001008568 Homo sapiens Laminin subunit beta-1 Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101000634835 Homo sapiens M1-specific T cell receptor alpha chain Proteins 0.000 description 1
- 101000763322 Homo sapiens M1-specific T cell receptor beta chain Proteins 0.000 description 1
- 101000986595 Homo sapiens Ornithine transcarbamylase, mitochondrial Proteins 0.000 description 1
- 101000728095 Homo sapiens Plasma membrane calcium-transporting ATPase 1 Proteins 0.000 description 1
- 101000728125 Homo sapiens Plasma membrane calcium-transporting ATPase 2 Proteins 0.000 description 1
- 101000728115 Homo sapiens Plasma membrane calcium-transporting ATPase 3 Proteins 0.000 description 1
- 101001134621 Homo sapiens Programmed cell death 6-interacting protein Proteins 0.000 description 1
- 101000616974 Homo sapiens Pumilio homolog 1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000651890 Homo sapiens Slit homolog 2 protein Proteins 0.000 description 1
- 101000651893 Homo sapiens Slit homolog 3 protein Proteins 0.000 description 1
- 101000753178 Homo sapiens Sodium/potassium-transporting ATPase subunit alpha-3 Proteins 0.000 description 1
- 101000753174 Homo sapiens Sodium/potassium-transporting ATPase subunit alpha-4 Proteins 0.000 description 1
- 101000974834 Homo sapiens Sodium/potassium-transporting ATPase subunit beta-3 Proteins 0.000 description 1
- 101000642688 Homo sapiens Syntaxin-3 Proteins 0.000 description 1
- 101000634836 Homo sapiens T cell receptor alpha chain MC.7.G5 Proteins 0.000 description 1
- 101000763321 Homo sapiens T cell receptor beta chain MC.7.G5 Proteins 0.000 description 1
- 101000612838 Homo sapiens Tetraspanin-7 Proteins 0.000 description 1
- 101000621459 Homo sapiens Vesicle transport through interaction with t-SNAREs homolog 1A Proteins 0.000 description 1
- 101000621456 Homo sapiens Vesicle transport through interaction with t-SNAREs homolog 1B Proteins 0.000 description 1
- 208000005503 Hyaluronidase deficiency Diseases 0.000 description 1
- 102100030358 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Human genes 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000003623 Hypoalbuminemia Diseases 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 101150091468 IGSF8 gene Proteins 0.000 description 1
- 101150018316 Igsf3 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100022516 Immunoglobulin superfamily member 2 Human genes 0.000 description 1
- 102100022519 Immunoglobulin superfamily member 3 Human genes 0.000 description 1
- 102100036489 Immunoglobulin superfamily member 8 Human genes 0.000 description 1
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 description 1
- 208000035343 Infantile neurovisceral acid sphingomyelinase deficiency Diseases 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102100033000 Integrin beta-4 Human genes 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 208000021342 Isolated sulfite oxidase deficiency Diseases 0.000 description 1
- 102100036015 Isoleucine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- 208000000420 Isovaleric acidemia Diseases 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- 208000003832 Kufor-Rakeb syndrome Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 101150117895 LAMP2 gene Proteins 0.000 description 1
- 102100039648 Lactadherin Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100027448 Laminin subunit beta-1 Human genes 0.000 description 1
- 102100034710 Laminin subunit gamma-1 Human genes 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 208000025121 Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000003221 Lysosomal acid lipase deficiency Diseases 0.000 description 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 1
- 108010009491 Lysosomal-Associated Membrane Protein 2 Proteins 0.000 description 1
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 201000010991 Marinesco-Sjogren syndrome Diseases 0.000 description 1
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 1
- 208000012583 Menkes disease Diseases 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700033011 Mitochondrial Complex II Deficiency Proteins 0.000 description 1
- 108700033252 Mitochondrial Complex III Deficiency Proteins 0.000 description 1
- 102100027891 Mitochondrial chaperone BCS1 Human genes 0.000 description 1
- 108700019255 Mitochondrial complex I deficiency Proteins 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 206010072927 Mucolipidosis type I Diseases 0.000 description 1
- 206010072928 Mucolipidosis type II Diseases 0.000 description 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
- 208000001769 Multiple Acyl Coenzyme A Dehydrogenase Deficiency Diseases 0.000 description 1
- 208000000149 Multiple Sulfatase Deficiency Disease Diseases 0.000 description 1
- 206010028182 Multiple congenital abnormalities Diseases 0.000 description 1
- 208000035032 Multiple sulfatase deficiency Diseases 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000027524 NESCAV syndrome Diseases 0.000 description 1
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 1
- 208000037355 Neurodegeneration due to 3-hydroxyisobutyryl-CoA hydrolase deficiency Diseases 0.000 description 1
- 201000000794 Niemann-Pick disease type A Diseases 0.000 description 1
- 201000000791 Niemann-Pick disease type B Diseases 0.000 description 1
- 102000005650 Notch Receptors Human genes 0.000 description 1
- 108010070047 Notch Receptors Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000000599 Ornithine Carbamoyltransferase Deficiency Disease Diseases 0.000 description 1
- 206010052450 Ornithine transcarbamoylase deficiency Diseases 0.000 description 1
- 208000035903 Ornithine transcarbamylase deficiency Diseases 0.000 description 1
- 102100028200 Ornithine transcarbamylase, mitochondrial Human genes 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 206010068786 Overlap syndrome Diseases 0.000 description 1
- 101150078890 POLG gene Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 240000000342 Palaquium gutta Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000016027 Parkinson disease 14 Diseases 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 102100029751 Plasma membrane calcium-transporting ATPase 1 Human genes 0.000 description 1
- 102100029744 Plasma membrane calcium-transporting ATPase 3 Human genes 0.000 description 1
- 108010053763 Pyruvate Carboxylase Proteins 0.000 description 1
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 description 1
- 208000021886 Pyruvate carboxylase deficiency Diseases 0.000 description 1
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 description 1
- 208000007738 Pyruvate dehydrogenase E2 deficiency Diseases 0.000 description 1
- 208000001821 Pyruvate dehydrogenase E3-binding protein deficiency Diseases 0.000 description 1
- 108700042837 Pyruvate dehydrogenase phosphatase deficiency Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 101100501116 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) TUF1 gene Proteins 0.000 description 1
- 208000013608 Salla disease Diseases 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 206010040037 Sensory neuropathy hereditary Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108700017825 Short chain Acyl CoA dehydrogenase deficiency Proteins 0.000 description 1
- 208000000828 Sialic Acid Storage Disease Diseases 0.000 description 1
- 208000017460 Sialidosis type 2 Diseases 0.000 description 1
- 102100027340 Slit homolog 2 protein Human genes 0.000 description 1
- 102100021952 Sodium/potassium-transporting ATPase subunit alpha-3 Human genes 0.000 description 1
- 102100021951 Sodium/potassium-transporting ATPase subunit alpha-4 Human genes 0.000 description 1
- 102100022792 Sodium/potassium-transporting ATPase subunit beta-3 Human genes 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 208000034972 Sudden Infant Death Diseases 0.000 description 1
- 206010042440 Sudden infant death syndrome Diseases 0.000 description 1
- 108700036932 Sulfite oxidase deficiency Proteins 0.000 description 1
- 108090000058 Syndecan-1 Proteins 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 102100026084 Syndecan-3 Human genes 0.000 description 1
- 108090000068 Syndecan-3 Proteins 0.000 description 1
- 102100037220 Syndecan-4 Human genes 0.000 description 1
- 108010055215 Syndecan-4 Proteins 0.000 description 1
- 102100035937 Syntaxin-3 Human genes 0.000 description 1
- 102100037219 Syntenin-1 Human genes 0.000 description 1
- 108010083130 Syntenins Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100029454 T cell receptor alpha chain MC.7.G5 Human genes 0.000 description 1
- 102100026967 T cell receptor beta chain MC.7.G5 Human genes 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 101150026786 TUFM gene Proteins 0.000 description 1
- 102100040952 Tetraspanin-7 Human genes 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 208000007824 Type A Niemann-Pick Disease Diseases 0.000 description 1
- 208000008291 Type B Niemann-Pick Disease Diseases 0.000 description 1
- 208000000983 UV-sensitive syndrome Diseases 0.000 description 1
- 208000016756 UV-sensitive syndrome 2 Diseases 0.000 description 1
- 102100023019 Vesicle transport through interaction with t-SNAREs homolog 1A Human genes 0.000 description 1
- 102100023018 Vesicle transport through interaction with t-SNAREs homolog 1B Human genes 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 208000026589 Wolman disease Diseases 0.000 description 1
- 208000006253 Woodhouse-Sakati syndrome Diseases 0.000 description 1
- 101000928515 Xenopus laevis Homeobox protein DLL-1 Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- BOPGDPNILDQYTO-NDOGXIPWSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4r,5r)-5-(3-carbamoyl-4h-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NDOGXIPWSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000002340 alkalosis Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 108010012864 alpha-Mannosidase Proteins 0.000 description 1
- 102000019199 alpha-Mannosidase Human genes 0.000 description 1
- 201000008333 alpha-mannosidosis Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000034779 autosomal dominant 9 intellectual disability Diseases 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000010310 bacterial transformation Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010055059 beta-Mannosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000005093 cerebellar hypoplasia Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000024042 cholesterol ester storage disease Diseases 0.000 description 1
- 208000013760 cholesteryl ester storage disease Diseases 0.000 description 1
- 208000035110 classic form autosomal dominant optic atrophy Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 201000003047 combined oxidative phosphorylation deficiency Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000001613 congenital disorder of glycosylation type IIn Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 208000026615 cytochrome-c oxidase deficiency disease Diseases 0.000 description 1
- 208000024515 deafness dystonia syndrome Diseases 0.000 description 1
- 201000008696 deafness-dystonia-optic neuronopathy syndrome Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 101150020338 dnaA gene Proteins 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- UKFXDFUAPNAMPJ-UHFFFAOYSA-N ethylmalonic acid Chemical compound CCC(C(O)=O)C(O)=O UKFXDFUAPNAMPJ-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- CNZOFNMWZBNPLL-OSKRVHINSA-L flot regimen Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)C(O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 CNZOFNMWZBNPLL-OSKRVHINSA-L 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 208000036917 glutaric acidemia IIa Diseases 0.000 description 1
- 208000036912 glutaric acidemia IIb Diseases 0.000 description 1
- 208000036904 glutaric acidemia IIc Diseases 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229920000588 gutta-percha Polymers 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 description 1
- 201000006847 hereditary sensory neuropathy Diseases 0.000 description 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
- 229950007870 hexadimethrine bromide Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000043353 human PUM1 Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 201000011286 hyperargininemia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000034435 immune system development Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 108700036927 isovaleric Acidemia Proteins 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010090909 laminin gamma 1 Proteins 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 201000002697 mitochondrial DNA depletion syndrome Diseases 0.000 description 1
- 208000010685 mitochondrial complex 5 (ATP synthase) deficiency nuclear type 5 Diseases 0.000 description 1
- 208000001043 mitochondrial complex I deficiency Diseases 0.000 description 1
- 208000007945 mitochondrial complex II deficiency Diseases 0.000 description 1
- 208000000188 mitochondrial complex III deficiency Diseases 0.000 description 1
- 201000001101 mitochondrial complex V (ATP synthase) deficiency Diseases 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 208000024933 mitochondrial proton-transporting ATP synthase complex deficiency Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000007769 mucolipidosis Diseases 0.000 description 1
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 description 1
- 201000002273 mucopolysaccharidosis II Diseases 0.000 description 1
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 description 1
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 description 1
- 201000003645 multiple acyl-CoA dehydrogenase deficiency Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 201000007599 neurodegeneration with brain iron accumulation 2a Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 208000033031 nuclear type 1 mitochondrial complex II deficiency Diseases 0.000 description 1
- 102000044158 nucleic acid binding protein Human genes 0.000 description 1
- 108700020942 nucleic acid binding protein Proteins 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 201000011278 ornithine carbamoyltransferase deficiency Diseases 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 201000007753 peroxisome biogenesis disorder 10A Diseases 0.000 description 1
- 208000022200 peroxisome biogenesis disorder 10A (Zellweger) Diseases 0.000 description 1
- 201000007752 peroxisome biogenesis disorder 11A Diseases 0.000 description 1
- 208000025336 peroxisome biogenesis disorder 11B Diseases 0.000 description 1
- 201000007755 peroxisome biogenesis disorder 12A Diseases 0.000 description 1
- 208000022222 peroxisome biogenesis disorder 12A (Zellweger) Diseases 0.000 description 1
- 201000007754 peroxisome biogenesis disorder 13A Diseases 0.000 description 1
- 208000022220 peroxisome biogenesis disorder 13A (Zellweger) Diseases 0.000 description 1
- 201000007800 peroxisome biogenesis disorder 1A Diseases 0.000 description 1
- 208000016032 peroxisome biogenesis disorder 1A (Zellweger) Diseases 0.000 description 1
- 201000007809 peroxisome biogenesis disorder 3A Diseases 0.000 description 1
- 208000025651 peroxisome biogenesis disorder 3A (Zellweger) Diseases 0.000 description 1
- 201000007811 peroxisome biogenesis disorder 4A Diseases 0.000 description 1
- 208000025522 peroxisome biogenesis disorder 4B Diseases 0.000 description 1
- 201000007757 peroxisome biogenesis disorder 5A Diseases 0.000 description 1
- 208000029302 peroxisome biogenesis disorder 5B Diseases 0.000 description 1
- 201000007756 peroxisome biogenesis disorder 6A Diseases 0.000 description 1
- 208000029282 peroxisome biogenesis disorder 6B Diseases 0.000 description 1
- 201000007759 peroxisome biogenesis disorder 7A Diseases 0.000 description 1
- 208000029304 peroxisome biogenesis disorder 7B Diseases 0.000 description 1
- 201000007758 peroxisome biogenesis disorder 8A Diseases 0.000 description 1
- 208000022280 peroxisome biogenesis disorder 8B Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000004012 propionic acidemia Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 description 1
- 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 description 1
- 208000003903 pyruvate dehydrogenase phosphatase deficiency Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- IYLGZMTXKJYONK-UHFFFAOYSA-N ruwenine Natural products O1C(=O)C(CC)(O)CC(C)C(C)(OC(C)=O)C(=O)OCC2=CCN3C2C1CC3 IYLGZMTXKJYONK-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000001392 short chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000025593 sulfite oxidase deficiency due to molybdenum cofactor deficiency type A Diseases 0.000 description 1
- 208000025594 sulfite oxidase deficiency due to molybdenum cofactor deficiency type B Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 125000000647 trehalose group Chemical group 0.000 description 1
- 208000030954 urea cycle disease Diseases 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 201000010866 very long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Manufacturing & Machinery (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1810301.0 | 2018-06-22 | ||
| GBGB1810301.0A GB201810301D0 (en) | 2018-06-22 | 2018-06-22 | Combinatorial gene therapy |
| PCT/EP2019/066471 WO2019243574A1 (en) | 2018-06-22 | 2019-06-21 | Combinatorial gene therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112955185A true CN112955185A (zh) | 2021-06-11 |
Family
ID=63042788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980042058.3A Pending CN112955185A (zh) | 2018-06-22 | 2019-06-21 | 联合基因治疗 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210252164A1 (https=) |
| EP (1) | EP3810206B1 (https=) |
| JP (1) | JP2021528407A (https=) |
| KR (1) | KR20210024040A (https=) |
| CN (1) | CN112955185A (https=) |
| AU (1) | AU2019289998A1 (https=) |
| BR (1) | BR112020026260A2 (https=) |
| CA (1) | CA3104432A1 (https=) |
| GB (1) | GB201810301D0 (https=) |
| IL (1) | IL279584A (https=) |
| MX (1) | MX2020013865A (https=) |
| SG (1) | SG11202012727SA (https=) |
| WO (1) | WO2019243574A1 (https=) |
| ZA (1) | ZA202100244B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3226019A1 (en) | 2021-07-20 | 2023-01-26 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their preparation, and uses |
| WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
| WO2023232976A1 (en) | 2022-06-03 | 2023-12-07 | Ags Therapeutics Sas | Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses |
| CN121038801A (zh) | 2022-10-24 | 2025-11-28 | Ags治疗简易股份公司 | 来自微藻的细胞外囊泡、它们在鼻内施用时的生物分布及其用途 |
| WO2025176847A1 (en) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Ocular delivery of active agents via microalgae extracellular vesicles |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7315001A (en) * | 2000-07-20 | 2002-01-30 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CN102813942A (zh) * | 2012-08-15 | 2012-12-12 | 钟志容 | 脂质超声微泡介导的腺相关病毒基因转染制剂及制备工艺 |
| WO2015002956A1 (en) * | 2013-07-01 | 2015-01-08 | Ohio State Innovation Foundation | Exosome delivery system |
| EP3090053A2 (en) * | 2013-12-30 | 2016-11-09 | CureVac AG | Artificial nucleic acid molecules |
| WO2017172606A1 (en) * | 2016-03-28 | 2017-10-05 | The Regents Of The University Of California | Method and composition for treating neuronal hyper-excitability |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| WO2016033695A1 (en) * | 2014-09-05 | 2016-03-10 | Exerkine Corporation | Exosome isolation |
| CA2962081A1 (en) * | 2014-09-26 | 2016-03-31 | Exerkine Corporation | Exosomes useful to treat lysosomal storage disease |
| GB2568255A (en) * | 2017-11-08 | 2019-05-15 | Evox Therapeutics Ltd | Exosomes comprising RNA therapeutics |
-
2018
- 2018-06-22 GB GBGB1810301.0A patent/GB201810301D0/en not_active Ceased
-
2019
- 2019-06-21 CA CA3104432A patent/CA3104432A1/en active Pending
- 2019-06-21 KR KR1020217001827A patent/KR20210024040A/ko not_active Withdrawn
- 2019-06-21 SG SG11202012727SA patent/SG11202012727SA/en unknown
- 2019-06-21 EP EP19732641.6A patent/EP3810206B1/en active Active
- 2019-06-21 AU AU2019289998A patent/AU2019289998A1/en not_active Abandoned
- 2019-06-21 JP JP2020570467A patent/JP2021528407A/ja active Pending
- 2019-06-21 CN CN201980042058.3A patent/CN112955185A/zh active Pending
- 2019-06-21 US US17/252,335 patent/US20210252164A1/en not_active Abandoned
- 2019-06-21 MX MX2020013865A patent/MX2020013865A/es unknown
- 2019-06-21 WO PCT/EP2019/066471 patent/WO2019243574A1/en not_active Ceased
- 2019-06-21 BR BR112020026260-9A patent/BR112020026260A2/pt not_active IP Right Cessation
-
2020
- 2020-12-20 IL IL279584A patent/IL279584A/en unknown
-
2021
- 2021-01-13 ZA ZA2021/00244A patent/ZA202100244B/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7315001A (en) * | 2000-07-20 | 2002-01-30 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CN102813942A (zh) * | 2012-08-15 | 2012-12-12 | 钟志容 | 脂质超声微泡介导的腺相关病毒基因转染制剂及制备工艺 |
| WO2015002956A1 (en) * | 2013-07-01 | 2015-01-08 | Ohio State Innovation Foundation | Exosome delivery system |
| EP3090053A2 (en) * | 2013-12-30 | 2016-11-09 | CureVac AG | Artificial nucleic acid molecules |
| WO2017172606A1 (en) * | 2016-03-28 | 2017-10-05 | The Regents Of The University Of California | Method and composition for treating neuronal hyper-excitability |
Non-Patent Citations (2)
| Title |
|---|
| 孟凡荣;陈琛;万海粟;周清华;: "慢病毒载体及其研究进展", 中国肺癌杂志, no. 12, pages 48 - 54 * |
| 王伟涛;: "外泌体――癌症的"双刃剑"", 生命世界, no. 09, pages 38 - 45 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3104432A1 (en) | 2019-12-26 |
| EP3810206B1 (en) | 2024-01-24 |
| MX2020013865A (es) | 2021-03-25 |
| EP3810206A1 (en) | 2021-04-28 |
| BR112020026260A2 (pt) | 2021-03-23 |
| US20210252164A1 (en) | 2021-08-19 |
| GB201810301D0 (en) | 2018-08-08 |
| JP2021528407A (ja) | 2021-10-21 |
| SG11202012727SA (en) | 2021-01-28 |
| AU2019289998A1 (en) | 2021-02-04 |
| KR20210024040A (ko) | 2021-03-04 |
| WO2019243574A1 (en) | 2019-12-26 |
| IL279584A (en) | 2021-03-01 |
| ZA202100244B (en) | 2022-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112955185A (zh) | 联合基因治疗 | |
| JP7586810B2 (ja) | ダノン病治療用遺伝子療法ベクター | |
| JP7208231B2 (ja) | 肺組織への標的化薬物及び遺伝子送達のためのシンシチンの使用 | |
| US20100266551A1 (en) | Adeno-associated viral vectors for the expression of dysferlin | |
| CA3078096A1 (en) | Use of syncytin for targeting drug and gene delivery to regenerating muscle tissue | |
| JP2023536008A (ja) | ベクター | |
| CA3162761A1 (en) | Apoe gene therapy | |
| KR20230025659A (ko) | Tdp-43 단백질병증의 치료를 위한 조성물 및 방법 | |
| JP2021533801A5 (https=) | ||
| US20230226223A1 (en) | Compositions and Methods for the Treatment of Protein Aggregation Disorders | |
| JP2023529371A (ja) | シヌクレイノパチーの処置のための組成物および方法 | |
| JP2023515442A (ja) | 筋肉特異的核酸調節エレメント及びその方法と使用 | |
| JP2023515443A (ja) | 核酸調節エレメントの新規な組合せ並びにその方法及び使用 | |
| US20250042958A1 (en) | Compositions and methods for the treatment of proteopathies | |
| US20240342313A1 (en) | Vector encoding rod-derived cone viability factor and human igk signal sequence | |
| WO2024236032A1 (en) | Gene therapies for phenylketonuria | |
| US20240025954A1 (en) | Compositions and Methods for the Treatment of Alzheimer's Disease | |
| US20210381002A1 (en) | Gene therapy for oxidative stress | |
| WO2025179154A1 (en) | Compositions and methods for enhancing transduction efficiency of viral vectors with heparin and analogues thereof | |
| Lettner et al. | Trans-splicing gene therapy in the KRT14 gene | |
| Evans et al. | Selected Oral Presentations | |
| Class et al. | Patent application title: CAPSID-MODIFIED RAAV VECTOR COMPOSITIONS AND METHODS THEREFOR Inventors: Arun Srivastava (Gainesville, FL, US) Arun Srivastava (Gainesville, FL, US) George V. Aslanidi (Gainesville, FL, US) Sergei Zolotukhin (Gainesville, FL, US) Sergei Zolotukhin (Gainesville, FL, US) Mavis Agbandje-Mckenna (Gainesville, FL, US) Kim M. Van Vliet (Gainesville, FL, US) Li Zhong (Boxborough, MA, US) Lakshmanan Govindasamy (Gainesville, FL, US) Assignees: University of Florida Research Foundation Inc. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210611 |